These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28835285)

  • 21. A methodological framework for drug development in rare diseases.
    Nony P; Kurbatova P; Bajard A; Malik S; Castellan C; Chabaud S; Volpert V; Eymard N; Kassai B; Cornu C; ;
    Orphanet J Rare Dis; 2014 Nov; 9():164. PubMed ID: 25774598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized controlled trial data for successful new drug application for rare diseases in the United States.
    Kubota Y; Narukawa M
    Orphanet J Rare Dis; 2023 Apr; 18(1):89. PubMed ID: 37076897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do we need authorized orphan drugs when compounded medications are available?
    Dooms M; Pincé H; Simoens S
    J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases.
    Lanar S; Acquadro C; Seaton J; Savre I; Arnould B
    Orphanet J Rare Dis; 2020 Jun; 15(1):134. PubMed ID: 32493385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review of available evidence on 11 high-priced inpatient orphan drugs.
    Kanters TA; de Sonneville-Koedoot C; Redekop WK; Hakkaart L
    Orphanet J Rare Dis; 2013 Aug; 8():124. PubMed ID: 23947946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?
    Menon D; Stafinski T; Dunn A; Short H
    Patient; 2015 Feb; 8(1):29-39. PubMed ID: 25516506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
    Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
    Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent Target.
    Miller KL; Lanthier M
    Health Aff (Millwood); 2016 Mar; 35(3):464-70. PubMed ID: 26953301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases.
    Enya K; Lim Y; Sengoku S; Kodama K
    Drug Discov Today; 2023 Oct; 28(10):103755. PubMed ID: 37648019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of orphan drug policies in treating rare diseases.
    Weerasooriya SU
    Health Info Libr J; 2019 Jun; 36(2):179-184. PubMed ID: 30933412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status and trend of clinical development of orphan drugs in China.
    Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
    Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation status of pharmacological studies in the development of orphan drugs.
    Yokoshiki S; Arato T
    Orphanet J Rare Dis; 2024 Jan; 19(1):5. PubMed ID: 38167464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
    Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.
    Nakayama H; Tsukamoto K
    Invest New Drugs; 2018 Aug; 36(4):702-708. PubMed ID: 29667133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.